Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Pathway Genomics Launches Hereditary Colorectal Cancer Genetic Test

Published: Thursday, February 20, 2014
Last Updated: Wednesday, February 19, 2014
Bookmark and Share
Test uses NGS technology to identify gene alterations or mutations.

Pathway Genomics Corporation has announced the launch of Hereditary Colorectal Cancer DNA InsightSM, the company’s premier hereditary cancer genetic test.

Based on a simple saliva sample, the test uses next-generation sequencing (NGS) technology to identify gene alterations or mutations that increase a patient’s risk of developing certain types of cancer.

“We are committed to providing valuable tools to help physicians further improve the quality of health care,” said David Becker, Ph.D., Pathway Genomics’ chief scientific officer. “Our new hereditary colorectal cancer genetic test is part of this commitment as it empowers physicians by providing useful information about cancer risk.”

The American Cancer Society estimates 140,000 colorectal cancer cases in the U.S. in 2013. Additionally, current research data shows, on average, one in 20 people develop colorectal cancer. People with a first-degree relative with colon cancer can have two to three times the risk of developing the disease.

“Colorectal cancer is the second-leading cause of cancer-related deaths in the United States,” said Linda Wasserman, M.D., Ph.D., Pathway Genomics’ laboratory director and former director of the Clinical Cancer Genetics Care Unit at UC San Diego Moores Cancer Center. “The genetic mutations that we test for can increase a patient’s lifetime risk for the development of colorectal cancer by as much as 50 to 80 percent.”

The Hereditary Colorectal Cancer DNA Insight genetic test scans a patient’s genome for a number of conditions related to colorectal cancer, including Lynch syndrome, familial adenomatous polyposis, Li-Fraumeni syndrome, juvenile polyposis, MUTYH-associated polyposis, Peutz-Jeghers syndrome, hereditary diffuse gastric cancer, and PTEN-hamartoma tumor syndrome. Additionally, many of the genes tested play a role in other cancer types, which will also be reported to the clinician.

As part of its cancer test, Pathway Genomics offers a complimentary Familial Studies Program, which provides genetic testing to family members of qualified patients who are found to have genetic mutations where the risk for cancer is not fully understood - known in the field as a variant of unknown significance (VUS). The test provides information on how the patient and family members may be affected.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Susan G. Komen and Pathway Genomics Sign National Agreement
Agreement to fund community breast cancer education and outreach programs in five cities nationwide.
Wednesday, September 10, 2014
Scientific News
Scientists Find Lethal Vulnerability in Treatment-Resistant Lung Cancer
The study describes how the drug Selinexor killed lung cancer cells and shrank tumors in mice when used against cancers driven by the aggressive and difficult-to-treat KRAS cancer gene.
Nanosensors Could Determine Tumours’ Ability to Remodel Tissue
Researchers design nanosensors that can profile tumours, focusing on protease levels.
Blood Pressure Drug May Boost Effectiveness of Lung Cancer Treatment
Researchers at Imperial College London have suggested that the blood pressure drug may make a type of lung cancer treatment more effective.
Developing Novel Ear Infection Treatments
Research team engineers antibiotic gel for treating middle ear infections.
Wearable Microscope Can Measure Fluorescent Dyes Through Skin
UCLA research could make monitoring disease biomarkers easier and more cost-effective.
Potential of New Insect Control Traits in Agriculture
Researchers have discovered a protein that shows promise as an alternate corn rootworm control mechanism.
Fighting Cancer with Sticky Nanoparticles
Treatment that uses bioadhesive nanoparticles drug carriers proved more effective than conventional treatments for certain cancers.
Fighting Plant Pathogens with RNA
Researchers develop strategy that could lead to environmentally friendly fungicide to fight pathogens.
Smart Material Hunts Cancers
Team has created smart material that locates and images cancer or tumour sites in tissue.
Examining mtDNA May Help Identify Unknown Ancestry That Influences Breast Cancer Risk
Researchers studying mtDNA in a group of triple negative breast cancer patients found that 13 percent of participants were unaware of ancestry that could influence their risk of cancer.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!